Hospital Healthcare Europe

1 week ago | hospitalhealthcare.com | Helen Quinn

Some bacteria have already become resistant to ceftazidime/avibactam – one of the new antibiotics introduced to the NHS in 2017. A new study published by the UK Health Security Agency (UKHSA) highlights the risk, and although the levels of resistance are currently low, it provides a stark reminder that appropriate antibiotic use is essential to slowing the development of resistance.

1 week ago | hospitalhealthcare.com | Helena Beer

The Pre-DX trial is investigating pre-operative Oncotype DX testing on core biopsy for breast cancer instead of the traditional post-operative approach. Here, with an introduction from Hospital Healthcare Europe editor Helena Beer, the lead investigator of the trial, Mr Henry Cain, discusses this ‘natural next step’ in the evolution of novel approaches to breast cancer diagnostics, what the trial found and how it’s set to transform clinical practice.

2 weeks ago | hospitalhealthcare.com | Helena Beer

Hospital Healthcare Europe is delighted to announce respiratory consultant and cystic fibrosis expert Dr Uta Hill as a speaker at the upcoming Clinical Excellence in Respiratory Care event on 7 May 2025. Dr Hill is the cystic fibrosis clinical lead and bronchiectasis co-clinical lead at the Cambridge Centre for Lung Infection at Royal Papworth Hospital NHS Foundation Trust. She will share her expert insights on redefining the clinical landscape of cystic fibrosis.

2 weeks ago | hospitalhealthcare.com | Helena Beer

NHS App services are being offered by 87% of hospitals in the UK, which has saved 1.26 million clinical hours since July, according to the Department of Health and Social Care (DHSC). Estimates also suggest that around 1.5 million missed hospital appointments have been prevented and 5.7 million staff hours saved in total over the past eight months, due to easier access to information and services through the app.

3 weeks ago | hospitalhealthcare.com | Jerome Smail

Timing the use of a commonly prescribed asthma inhaler in the mid-afternoon could lead to improved clinical outcomes, according to new research led by the University of Manchester. The study, published in the journal Thorax, found that a once-daily dose of inhaled beclomethasone was most effective when taken between 3pm and 4pm. The findings suggest that aligning asthma medication with the body’s natural circadian rhythms could enhance its effectiveness without increasing the dose.